Chimeric antigen receptor and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9821012-B2
Application number	US-201715419729-A
Country	US
Kind code	B2
Filing date	Jan 30, 2017
Priority date	Feb 15, 2013
Publication date	Nov 21, 2017
Grant date	Nov 21, 2017

Abstract

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

First claim

What is claimed is:

1. One or more isolated nucleic acids comprising one or more nucleotide sequences encoding a first polypeptide and a second polypeptide of a heterodimeric chimeric antigen receptor (CAR), wherein the first and the second polypeptides are two separate polypeptides, such that when present in a eukaryotic cell membrane, the first polypeptide of the CAR binds an antigen and the CAR dimerizes in the presence of a small molecule dimerizer to produce titratable activity of the CAR, wherein:
a) the first polypeptide comprises:
i) an extracellular antigen binding domain that specifically binds to the antigen on target cells;
ii) a transmembrane domain; and
iii) a first member of a dimerization pair; and

b) the second polypeptide comprises:
i) a transmembrane domain;
ii) a second member of the dimerization pair; and
iii) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM), wherein the intracellular signaling domain provides signal transduction activity,

wherein the second polypeptide does not comprise an antigen-binding domain,
wherein the first polypeptide, the second polypeptide or both the first and second polypeptides comprise an intracellular costimulatory polypeptide.

2. The one or more isolated nucleic acids according to claim 1 , wherein the one or more isolated nucleic acids is a single nucleic acid comprising nucleotide sequences encoding the first and the second polypeptides of the heterodimeric CAR.

3. The one or more isolated nucleic acids according to claim 1 , wherein the one or more isolated nucleic acids comprises a first nucleic acid and a second nucleic acid, wherein the first nucleic acid comprises a first nucleotide sequence encoding the first polypeptide of the heterodimeric CAR and the second nucleic acid comprises a second nucleotide sequence encoding the second polypeptide of the heterodimeric CAR.

4. The one or more isolated nucleic acids according to claim 1 , wherein the extracellular antigen binding domain comprises an antigen-binding portion of an antibody.

5. The one or more isolated nucleic acids according to claim 1 , wherein the first polypeptide comprises a hinge region interposed between the extracellular antigen binding domain and the transmembrane domain.

6. The one or more isolated nucleic acids according to claim 5 , wherein the hinge region is an immunoglobulin IgG hinge region or a hinge derived from CD8.

7. The one or more isolated nucleic acids according to claim 1 , wherein the intracellular signaling domain comprising the ITAM is selected from the group consisting of CD3-zeta and ZAP70.

8. The one or more isolated nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair form a heterodimer in the presence of the small molecule dimerizer.

9. The one or more isolated nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair form a homodimer in the presence of the small molecule dimerizer.

10. The one or more isolated nucleic acids according to claim 8 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP-rapamycin associated protein (FRB);
b) a Gibberellic Acid Insensitive (GAI) protein and a gibberellin receptor (GID1) protein;
c) FKBP and calcineurin catalytic subunit A (CnA);
d) an abscisic acid receptor (PYL) protein and an abscissic acid insensitive (ABI) protein;
e) a cryptochrome 2 (Cry2) protein and a transcription factor bHLH63 (CIB1) protein; and
f) FKBP and cyclophilin.

11. The one or more isolated nucleic acids according to claim 9 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP;
b) gyrase B (GyrB) and GyrB;
c) dihydrofolate reductase (DHFR) and DHFR; and
d) DmrB and DmrB.

12. The one or more isolated nucleic acids according to claim 10 , wherein the first member of the dimerization pair is an FK506 binding protein (FKBP), and wherein the second member of the dimerization pair is a FKBP-rapamycin associated protein (FRB).

13. The one or more isolated nucleic acids according to claim 12 , wherein the FKBP comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:12, and wherein the FRB comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:14.

14. The one or more isolated nucleic acids according to claim 10 , wherein the first member of the dimerization pair is GID1, and wherein the second member of the dimerization pair is GAI.

15. The one or more isolated nucleic acids according to claim 14 , wherein the GID1 polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in one of SEQ ID NOs:95-97, and wherein the GAI polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:94.

16. The one or more isolated nucleic acids according to claim 1 , wherein the extracellular antigen binding domain binds an epitope present on a cancer cell.

17. The one or more isolated nucleic acids according to claim 16 , wherein the cancer cell is a breast cancer cell, a B cell lymphoma, a Hodgkin lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma, a lung cancer cell, a non-Hodgkin B-cell lymphoma cell, an ovarian cancer cell, a prostate cancer cell, a mesothelioma cell, a melanoma cell, a chronic lymphocytic leukemia cell, an acute lymphocytic leukemia cell, a neuroblastoma cell, a glioma, a glioblastoma, a medulloblastoma, or a colorectal cancer cell.

18. The one or more isolated nucleic acids according to claim 1 , wherein the one or more nucleotide sequences are operably linked to-one or more T lymphocyte-specific promoters.

19. The one or more isolated nucleic acids according to claim 1 , wherein the one or more nucleotide sequences are operably linked to one or more NK cell-specific promoters.

20. The one or more isolated nucleic acids according to claim 1 , wherein the intracellular costimulatory polypeptide is selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.

21. The one or more isolated nucleic acids according to claim 20 , wherein the 4-1BB polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:24.

22. The one or more isolated nucleic acids according to claim 20 , wherein the OX-40 polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:65.

23. The one or more isolated nucleic acids according to claim 20 , wherein the CD28 polypeptide comprises an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:63.

24. The one or more isolated nucleic acids according to claim 1 , wherein the first polypeptide comprises a first costimulatory polypeptide comprising an amino acid sequence and the second polypeptide comprises a second costimulatory polypeptide comprising an amino acid sequence that has at least 95% amino acid identity to the amino

Assignees

• Univ California

Inventors

• Wu Chia-Yung
• Onuffer James
• Lim Wendell A

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title

• C12Y502/01008

  Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin · CPC title

• C07K2319/00

  Fusion polypeptide · CPC title